Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vera Therapeutics ( (VERA) ) has issued an announcement.
On June 2, 2025, Vera Therapeutics announced positive results from its ORIGIN Phase 3 clinical trial of atacicept in adult patients with IgA nephropathy, showing a 46% reduction in proteinuria compared to baseline and a 42% reduction compared to placebo at week 36. The trial’s success marks a significant step for Vera Therapeutics, as they plan to submit a Biologics License Application to the FDA for accelerated approval in the fourth quarter of 2025, potentially leading to a commercial launch in 2026. These results highlight atacicept’s potential to transform the treatment landscape for IgA nephropathy and other autoimmune diseases.
The most recent analyst rating on (VERA) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.
Spark’s Take on VERA Stock
According to Spark, TipRanks’ AI Analyst, VERA is a Underperform.
Vera Therapeutics’ overall stock score is driven by ongoing financial challenges, including consistent losses and negative cash flows, despite a strong equity position. Technical analysis indicates bearish momentum, with the stock underperforming key moving averages. The valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on VERA stock, click here.
More about Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Its lead product candidate is atacicept, a fusion protein designed to block B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which are involved in autoimmune diseases such as IgA nephropathy and lupus nephritis.
Average Trading Volume: 1,048,787
Technical Sentiment Signal: Sell
Current Market Cap: $1.21B
Find detailed analytics on VERA stock on TipRanks’ Stock Analysis page.